BioSpace News Archive

Applied DNA Sciences has signed a new CertainT trademark license agreement with Palmetto Synthetics (“Palmetto”), a leader in the production of high quality, specialty synthetic fiber.

EXACT Sciences today announced that the company plans to release its third-quarter 2017 financial results after the close of the U.S. financial markets on Oct. 30.

Cerevance announced that Jeremy Nathans, M.D., Ph.D., has joined the company as a senior-level scientific advisor.

Viking today announced positive final results from an eight-week study of VK2809 in an in vivo model of NASH.

On October 19 ACRO Executive Director Doug Peddicord, Ph.D., testified at a public hearing of the New Jersey Division of Consumer Affairs about a regulation that, if adopted, would have a devastating impact on the availability of clinical trials for patients in New Jersey and cripple the ability of New Jersey physicians to conduct industry-sponsored clinical trial research on investigational therapies.

Biohaven and its wholly owned subsidiary, Biohaven Pharma, today announced that the FDA has notified the Company that it may proceed with its clinical investigation of trigriluzole, a novel glutamate modulator, as a potential treatment for patients with OCD.

Today, Cook Group completed the sale of Cook Pharmica to Catalent, Inc., Cook Pharmica, now known as Catalent Bloomington, expands Catalent’s capabilities by adding more drug substance and drug product expertise and capacity to serve patients worldwide.

Mazor Robotics Ltd. announced today that it will report financial results for the third quarter ended September 30, 2017, before the U.S. markets open on Tuesday, November 7, 2017.